Laurent Massuyeau – CEO, iQone Healthcare, Switzerland
Laurent Massuyeau introduces Swiss biosimilar commercialisation specialist iQone healthcare, why it made sense to base the company in Switzerland, its…
Tagged with Biosimilars
Dan Leonard – President & CEO, Association for…
Dan Leonard, president and CEO of the Association for Accessible Medicines (AAM) since August 2020, outlines his key agenda priorities as head of the…
China: Yangtze River Pharmaceutical Group (YRPG) in Profile
One of the largest domestic pharma companies in China (ranking number one from 2014 to 2019), Yangtze River Pharmaceutical Group (YRPG) is so-named…
Securing the Conditions to Secure Our Meds
The AAM’s Dan Leonard highlights the savings impact that generic and biosimilar have on US healthcare today and introduces the ‘Secure Our Meds’…
Alvotech’s Four Traits for Biosimilars Success
Alvotech – the biosimilars arm of Icelandic-headquartered generics player Alvogen – is positioning itself for future growth via a very different…
Anil Okay – General Manager, Adalvo & Chief Commercial…
CCO Anil Okay introduces how Alvotech’s focus on biosimilars, comprehensive platform, differentiated portfolio approach, and commercial strategy…
Top 10 Global Generics & Biosimilars Companies
The top ten global generics and biosimilars companies according to a recent Informa Pharma Intelligence ranking for 2019. Sandoz leads the way in…
Viatris: Cost-Cutting Needed at New Generics Behemoth
In November 2020, after months of delay caused by COVID-19 disruptions and a US antitrust roadblock, Mylan and Pfizer's Upjohn generics unit finally…
The Value Proposition of Generics & Biosimilars in the USA
AAM President Dan Leonard highlights the findings of the association’s most recent report and re-states the value proposition of generic and…
Jan Tangermann – Country Head, Sandoz Switzerland
Sandoz Switzerland’s Jan Tangermann highlights the importance of the Swiss affiliate to the global group and how it was able to provide sustainable…
Biosimilar Adoption in the US: Still Lagging Behind Europe
As part of our upcoming US Healthcare and Life Sciences Review, we spoke to key stakeholders – former Association for Accessible Medicines (AAM)…
Alper Ureten – VP, General Manager for Biosimilars…
Alper Ureten, Amgen VP and General Manager, sits down with PharmaBoardroom to set out his ambitions and objectives for its Biosimilars Business Unit.…
